Intercell: Restructuring Is Progressing

Companies › Health Care ♦ Published: August 16, 2011; 10:54 ♦ (Vindobona)

Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

Intercell: Restructuring Is Progressing / Picture: © Intercell

The listed vaccine producer Intercell on Tuesday presented results for the second quarter and the first half of 2011. Revenue increased by 27.5% to € 18.38m from January to June. Net loss was reduced by 44.2% and amounted to € 12.9m which is still 70% of revenue.

Sales of the company’s only product currently on the market, a vaccine to prevent Japanese Encephalitis…

or Log In

Fast News Search
Related News
Intercell Is Looking for Financial Investors (July 19, 2011)
Intercell: “We Will Stabilize Our Share Price” (June 21, 2011)
Intercell to Cut Jobs and Research Budget (June 8, 2011)
Intercell: Sale Is No Longer Ruled Out (May 10, 2011)
Lingelbach New CEO for Intercell (May 5, 2011)
Intercell starts a confirmatory clinical study using the Vaccine Enhancement (May 4, 2011)
Read More
Intercell, Earnings, High Tech Industry, Health Policy, Pharmaceutical Industry
Featured
Coronavirus in Lower Austria: Update
See latest Vindobona Newsletter